Correction to Discovery of Small Molecule Mer Kinase Inhibitors for the

Correction to Discovery of Small Molecule Mer Kinase Inhibitors for the

Aug 15, 2014 - for the Treatment of Pediatric Acute Lymphoblastic Leukemia. Jing Liu, Chao Yang, Catherine Simpson, Deborah DeRyckere, Amy Van ...

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment

Nov 4, 2013 - An exemplar from the furo[2,3-d]pyrimidine series showed a dose proportional .... compared to TNFÎ± alone, at doses of 0.2, 2.0, and 20 mg/kg, respectively (Figure 4). ..... to renal ischemia/reperfusion injury Kidney Int. 2012, 81, 751

Discovery of Small Molecule RIP1 Kinase Inhibitors for the

Potent inhibitors of RIP1 kinase from three distinct series, 1-aminoisoquinolines, pyrrolo[2,3-b]pyridines, and furo[2,3-d]pyrimidines, all of the type II class recognizing a DLG-out inactive conformation, were identified from screening of our in-hou

Correction to Discovery of Small-Molecule Inhibitors Selectively

Jan 24, 2017 - Huifang Li, Fuqiang Ban, Kush Dalal, Eric Leblanc, Kate Frewin, Dennis Ma, Hans Adomat, Paul S. Rennie, and Artem Cherkasov*. J. Med.


Jan 24, 2017 - Huifang Li, Fuqiang Ban, Kush Dalal, Eric Leblanc, Kate Frewin, Dennis Ma, Hans Adomat,. Paul S. Rennie, and Artem Cherkasov*. Journal of ...


Jan 24, 2017 - Huifang Li, Fuqiang Ban, Kush Dalal, Eric Leblanc, Kate Frewin, Dennis Ma, Hans Adomat,. Paul S. Rennie, and Artem Cherkasov*. Journal of ...

Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment

Aug 18, 2014 - Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis. Weihe Zhang, Andrew L. McIver, Michael ...

Discovery of Mer Specific Tyrosine Kinase Inhibitors for the

â Center for Integrative Chemical Biology and Drug Discovery â¡Division of ... Department of Pediatrics, School of Medicine, University of Colorado Denver ...

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to

Jan 18, 2012 - The importance of the G2019S mutation in the kinase domain of LRRK2 derives from the association with the second most common neurodegenerative disease: Parkinson's disease. The late-onset sporadic classical PD affects almost 2% of the

Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer

Jul 14, 2016 - Biography. Timothy P. Heffron is a Senior Scientist at Genentech. As a medicinal chemist and chemistry and research team leader, Timothy has contributed to the advancement of programs directed toward treatments for neurooncology, oncol

Correction to Discovery of Small Molecule Mer Kinase Inhibitors for the

Recommend Documents